FGF4
Summary: The protein encoded by this gene is a member of the fibroblast growth factor (FGF) family. FGF family members possess broad mitogenic and cell survival activities and are involved in a variety of biological processes including embryonic development, cell growth, morphogenesis, tissue repair, tumor growth and invasion. This gene was identified by its oncogenic transforming activity. This gene and FGF3, another oncogenic growth factor, are located closely on chromosome 11. Co-amplification of both genes was found in various kinds of human tumors. Studies on the mouse homolog suggested a function in bone morphogenesis and limb development through the sonic hedgehog (SHH) signaling pathway. [provided by RefSeq, Jul 2008].
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| fibroblast growth factor 4 | MIM:164980 | Ensembl:ENSG00000075388 | HGNC:HGNC:3682 | PA28121 | 11q13.3 |
GO terms in FGF4
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| MF | TAS | GO:0004713 | protein tyrosine kinase activity |
| MF | TAS | GO:0005088 | Ras guanyl-nucleotide exchange factor activity |
| MF | IEA | GO:0005104 | fibroblast growth factor receptor binding |
| MF | IEA | GO:0008083 | growth factor activity |
| MF | IEA | GO:0008201 | heparin binding |
| MF | TAS | GO:0016303 | 1-phosphatidylinositol-3-kinase activity |
| MF | TAS | GO:0046934 | phosphatidylinositol-4,5-bisphosphate 3-kinase activity |
| CC | TAS | GO:0005576 | extracellular region |
| CC | IEA | GO:0005622 | intracellular |
| BP | TAS | GO:0000165 | MAPK cascade |
| BP | IEA | GO:0001502 | cartilage condensation |
| BP | TAS | GO:0007165 | signal transduction |
| BP | TAS | GO:0007267 | cell-cell signaling |
| BP | IGI | GO:0008284 | positive regulation of cell proliferation |
| BP | IGI | GO:0008543 | fibroblast growth factor receptor signaling pathway |
| BP | TAS | GO:0008543 | fibroblast growth factor receptor signaling pathway |
| BP | IDA | GO:0010463 | mesenchymal cell proliferation |
| BP | IEA | GO:0010469 | regulation of signaling receptor activity |
| BP | IEA | GO:0018108 | peptidyl-tyrosine phosphorylation |
| BP | IEA | GO:0019827 | stem cell population maintenance |
| BP | IEA | GO:0035116 | embryonic hindlimb morphogenesis |
| BP | IEA | GO:0036092 | phosphatidylinositol-3-phosphate biosynthetic process |
| BP | IEA | GO:0042475 | odontogenesis of dentin-containing tooth |
| BP | IEA | GO:0043066 | negative regulation of apoptotic process |
| BP | IEA | GO:0045944 | positive regulation of transcription by RNA polymerase II |
| BP | IEA | GO:0046854 | phosphatidylinositol phosphorylation |
| BP | IEA | GO:0051781 | positive regulation of cell division |
| BP | TAS | GO:0051897 | positive regulation of protein kinase B signaling |
| BP | IEA | GO:0060363 | cranial suture morphogenesis |
| BP | IEA | GO:0060561 | apoptotic process involved in morphogenesis |
| BP | IDA | GO:0060591 | chondroblast differentiation |
| BP | IDA | GO:0070374 | positive regulation of ERK1 and ERK2 cascade |
| BP | IEA | GO:1990830 | cellular response to leukemia inhibitory factor |
| BP | IDA | GO:2000544 | regulation of endothelial cell chemotaxis to fibroblast growth factor |
Gene expression in normal tissue: FGF4
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in FGF4
| Database | Pathway ID | Pathway Des. |
|---|---|---|
| reactome | R-HSA-109704 | PI3K Cascade |
| reactome | R-HSA-112399 | IRS-mediated signalling |
| reactome | R-HSA-1226099 | Signaling by FGFR in disease |
| reactome | R-HSA-1257604 | PIP3 activates AKT signaling |
| reactome | R-HSA-162582 | Signal Transduction |
| reactome | R-HSA-1643685 | Disease |
| reactome | R-HSA-1839122 | Signaling by activated point mutants of FGFR1 |
| reactome | R-HSA-1839124 | FGFR1 mutant receptor activation |
| reactome | R-HSA-1839126 | FGFR2 mutant receptor activation |
| reactome | R-HSA-1839130 | Signaling by activated point mutants of FGFR3 |
| reactome | R-HSA-190236 | Signaling by FGFR |
| reactome | R-HSA-190239 | FGFR3 ligand binding and activation |
| reactome | R-HSA-190241 | FGFR2 ligand binding and activation |
| reactome | R-HSA-190242 | FGFR1 ligand binding and activation |
| reactome | R-HSA-190322 | FGFR4 ligand binding and activation |
| reactome | R-HSA-190372 | FGFR3c ligand binding and activation |
| reactome | R-HSA-190373 | FGFR1c ligand binding and activation |
| reactome | R-HSA-190375 | FGFR2c ligand binding and activation |
| reactome | R-HSA-199418 | Negative regulation of the PI3K/AKT network |
| reactome | R-HSA-2033514 | FGFR3 mutant receptor activation |
| reactome | R-HSA-2033519 | Activated point mutants of FGFR2 |
| reactome | R-HSA-2219528 | PI3K/AKT Signaling in Cancer |
| reactome | R-HSA-2219530 | Constitutive Signaling by Aberrant PI3K in Cancer |
| reactome | R-HSA-2404192 | Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) |
| reactome | R-HSA-2428924 | IGF1R signaling cascade |
| reactome | R-HSA-2428928 | IRS-related events triggered by IGF1R |
| reactome | R-HSA-5654219 | Phospholipase C-mediated cascade: FGFR1 |
| reactome | R-HSA-5654221 | Phospholipase C-mediated cascade; FGFR2 |
| reactome | R-HSA-5654227 | Phospholipase C-mediated cascade; FGFR3 |
| reactome | R-HSA-5654228 | Phospholipase C-mediated cascade; FGFR4 |
| reactome | R-HSA-5654687 | Downstream signaling of activated FGFR1 |
| reactome | R-HSA-5654688 | SHC-mediated cascade:FGFR1 |
| reactome | R-HSA-5654689 | PI-3K cascade:FGFR1 |
| reactome | R-HSA-5654693 | FRS-mediated FGFR1 signaling |
| reactome | R-HSA-5654695 | PI-3K cascade:FGFR2 |
| reactome | R-HSA-5654696 | Downstream signaling of activated FGFR2 |
| reactome | R-HSA-5654699 | SHC-mediated cascade:FGFR2 |
| reactome | R-HSA-5654700 | FRS-mediated FGFR2 signaling |
| reactome | R-HSA-5654704 | SHC-mediated cascade:FGFR3 |
| reactome | R-HSA-5654706 | FRS-mediated FGFR3 signaling |
| reactome | R-HSA-5654708 | Downstream signaling of activated FGFR3 |
| reactome | R-HSA-5654710 | PI-3K cascade:FGFR3 |
| reactome | R-HSA-5654712 | FRS-mediated FGFR4 signaling |
| reactome | R-HSA-5654716 | Downstream signaling of activated FGFR4 |
| reactome | R-HSA-5654719 | SHC-mediated cascade:FGFR4 |
| reactome | R-HSA-5654720 | PI-3K cascade:FGFR4 |
| reactome | R-HSA-5654726 | Negative regulation of FGFR1 signaling |
| reactome | R-HSA-5654727 | Negative regulation of FGFR2 signaling |
| reactome | R-HSA-5654732 | Negative regulation of FGFR3 signaling |
| reactome | R-HSA-5654733 | Negative regulation of FGFR4 signaling |
| reactome | R-HSA-5654736 | Signaling by FGFR1 |
| reactome | R-HSA-5654738 | Signaling by FGFR2 |
| reactome | R-HSA-5654741 | Signaling by FGFR3 |
| reactome | R-HSA-5654743 | Signaling by FGFR4 |
| reactome | R-HSA-5655253 | Signaling by FGFR2 in disease |
| reactome | R-HSA-5655302 | Signaling by FGFR1 in disease |
| reactome | R-HSA-5655332 | Signaling by FGFR3 in disease |
| reactome | R-HSA-5658623 | FGFRL1 modulation of FGFR1 signaling |
| reactome | R-HSA-5663202 | Diseases of signal transduction |
| reactome | R-HSA-5673001 | RAF/MAP kinase cascade |
| reactome | R-HSA-5683057 | MAPK family signaling cascades |
| reactome | R-HSA-5684996 | MAPK1/MAPK3 signaling |
| reactome | R-HSA-6811558 | PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling |
| reactome | R-HSA-74751 | Insulin receptor signalling cascade |
| reactome | R-HSA-74752 | Signaling by Insulin receptor |
| reactome | R-HSA-8853338 | Signaling by FGFR3 point mutants in cancer |
| reactome | R-HSA-9006925 | Intracellular signaling by second messengers |
| reactome | R-HSA-9006934 | Signaling by Receptor Tyrosine Kinases |
| wikipathways | WP2848 | Differentiation Pathway |
| wikipathways | WP3584 | MECP2 and Associated Rett Syndrome |
| wikipathways | WP382 | MAPK Signaling Pathway |
| wikipathways | WP3931 | ESC Pluripotency Pathways |
| wikipathways | WP3932 | Focal Adhesion-PI3K-Akt-mTOR-signaling pathway |
| wikipathways | WP4172 | PI3K-Akt Signaling Pathway |
| wikipathways | WP51 | Regulation of Actin Cytoskeleton |
| kegg | hsa04010 | MAPK signaling pathway - Homo sapiens (human) |
| kegg | hsa04014 | Ras signaling pathway - Homo sapiens (human) |
| kegg | hsa04015 | Rap1 signaling pathway - Homo sapiens (human) |
| kegg | hsa04151 | PI3K-Akt signaling pathway - Homo sapiens (human) |
| kegg | hsa04810 | Regulation of actin cytoskeleton - Homo sapiens (human) |
| kegg | hsa05200 | Pathways in cancer - Homo sapiens (human) |
| kegg | hsa05218 | Melanoma - Homo sapiens (human) |
| kegg | hsa05224 | Breast cancer - Homo sapiens (human) |
| kegg | hsa05226 | Gastric cancer - Homo sapiens (human) |
| pid | ajdiss_2pathway | Posttranslational regulation of adherens junction stability and dissassembly |
| pid | betacatenin_nuc_pathway | Regulation of nuclear beta catenin signaling and target gene transcription |
| pid | fgf_pathway | FGF signaling pathway |
| pid | syndecan_1_pathway | Syndecan-1-mediated signaling events |
| pid | syndecan_2_pathway | Syndecan-2-mediated signaling events |
| pid | syndecan_3_pathway | Syndecan-3-mediated signaling events |
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD634 | SCHEMBL2608041 | 2 |
| iGMDRD211 | (1S,3R)-RSL3 | 2 |
| iGMDRD314 | Tanespimycin | 2 |
| iGMDRD61 | Kinetin riboside | 5 |
| iGMDRD567 | E-3810 | 1 |
| iGMDRD523 | Cyanoquinoline, 11 | 3 |
| iGMDRD494 | Neopeltolide | 2 |
| iGMDRD405 | PIK-75 | 2 |
| iGMDRD424 | Tamatinib | 1 |
| iGMDRD144 | NSC95397 | 2 |
| iGMDRD126 | Tipifarnib | 1 |
| iGMDRD307 | Manumycin A | 1 |
| iGMDRD23 | Gossypol | 5 |
| iGMDRD329 | Merck60 | 2 |
| iGMDRD562 | Navitoclax | 8 |
| iGMDRD871 | BRD6368 | 8 |
| iGMDRD887 | Compound 23 citrate | 3 |
| iGMDRD441 | TW 37 | 2 |
| iGMDRD267 | Oligomycin A | 3 |
| iGMDRD674 | Dovitinib | 2 |
| iGMDRD255 | SB225002 | 3 |
| iGMDRD137 | Indisulam | 2 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in FGF4
CLASSFICATION
Copyright © 2018 Modellab | All Rights Reserved
Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.